| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
PCVX
Vaxcyte
|
Jul 14, 2026 | BUY |
Strong Buy
+75.4% avg upside
15 analysts
|
$116.00
103.38% Upside
|
· |
|
MBX
MBX Biosciences, Inc.
|
Jul 14, 2026 | BUY |
Strong Buy
+9.6% avg upside
14 analysts
|
$88.00
46.66% Upside
|
· |
|
LLY
Eli Lilly & Co
|
Jul 13, 2026 | BUY |
Strong Buy
-12.7% avg upside
47 analysts
|
$1273.00
7.65% Upside
|
+0.0% |
|
GB:AZN
AstraZeneca
|
Jul 09, 2026 | BUY |
Strong Buy
+17.1% avg upside
26 analysts
|
$16200.00
28.96% Upside
|
· |
|
SNY
Sanofi
|
Jul 09, 2026 | HOLD |
Strong Buy
+67.2% avg upside
20 analysts
|
— | +0.2% |
|
BMY
Bristol-Myers Squibb
|
Jul 09, 2026 | BUY |
Buy
+0.2% avg upside
42 analysts
|
$72.00
21.34% Upside
|
-0.6% |
|
SEPN
Septerna, Inc.
|
Jul 01, 2026 | BUY |
Strong Buy
+32.5% avg upside
12 analysts
|
$45.00
30.91% Upside
|
+5.0% |
|
AMLX
Amylyx Pharmaceuticals Inc
|
Jun 26, 2026 | BUY |
Strong Buy
+41.2% avg upside
14 analysts
|
$40.00
129.74% Upside
|
+0.5% |
|
GENB
Generate Biomedicines, Inc.
|
Jun 24, 2026 | BUY |
Strong Buy
+77.1% avg upside
6 analysts
|
$30.00
110.07% Upside
|
· |
|
APGE
Apogee Therapeutics
|
Jun 23, 2026 | HOLD |
Buy
-7.4% avg upside
19 analysts
|
— | +0.7% |
|
TENX
Tenax Therapeutics
|
Jun 22, 2026 | BUY |
Strong Buy
+147.6% avg upside
8 analysts
|
$40.00
150.36% Upside
|
· |
|
RYTM
Rhythm Pharmaceuticals
|
Jun 15, 2026 | BUY |
Strong Buy
+12.9% avg upside
19 analysts
|
$143.00
32.94% Upside
|
+19.8% |
|
IVA
Inventiva
|
May 27, 2026 | BUY |
Strong Buy
+272.2% avg upside
16 analysts
|
$11.00
155.85% Upside
|
-19.4% |
|
ARQT
Arcutis Biotherapeutics
|
May 26, 2026 | BUY |
Strong Buy
+44.1% avg upside
14 analysts
|
$35.00
29.06% Upside
|
+27.0% |
|
MLYS
Mineralys Therapeutics, Inc.
|
May 18, 2026 | BUY |
Strong Buy
+62.3% avg upside
12 analysts
|
$48.00
73.92% Upside
|
+7.5% |
|
ARCT
Arcturus Therapeutics
|
May 11, 2026 | HOLD |
Buy
+330.3% avg upside
36 analysts
|
— | · |
|
ACRS
Aclaris Therapeutics
|
May 11, 2026 | BUY |
Strong Buy
+81.6% avg upside
15 analysts
|
$12.00
118.18% Upside
|
+12.3% |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
May 07, 2026 | BUY |
Strong Buy
+99.3% avg upside
17 analysts
|
$140.00
171.12% Upside
|
+40.8% |
|
SGMT
Sagimet Biosciences, Inc. Class A
|
Apr 29, 2026 | BUY |
Strong Buy
+293.1% avg upside
15 analysts
|
$25.00
249.55% Upside
|
-14.3% |
|
FR:SAN
Sanofi
|
Oct 08, 2025 | BUY |
Strong Buy
+28.2% avg upside
30 analysts
|
$101.00
32.74% Upside
|
· |
|
NVO
Novo Nordisk
|
Apr 17, 2025 | HOLD |
Buy
+135.2% avg upside
26 analysts
|
— | -26.9% |
|
ALT
Altimmune
|
Apr 03, 2025 | HOLD |
Strong Buy
+787.5% avg upside
20 analysts
|
— | -25.1% |
|
GB:0QIU
Novo Nordisk
|
Jan 17, 2025 | BUY |
Buy
+27.2% avg upside
29 analysts
|
$798.00
147.23% Upside
|
· |
|
GB:GSK
GlaxoSmithKline
|
Oct 31, 2024 | HOLD |
Hold
-2.9% avg upside
25 analysts
|
— | · |
|
GSK
GlaxoSmithKline
|
Oct 31, 2024 | HOLD |
Buy
-16.6% avg upside
19 analysts
|
— | +33.3% |
|
MRK
Merck & Company
|
Jan 29, 2024 | BUY |
Strong Buy
+4.3% avg upside
43 analysts
|
$130.00
4.87% Upside
|
-16.8% |
|
ZLAB
Zai Lab
|
Oct 14, 2022 | BUY |
Strong Buy
+197.8% avg upside
13 analysts
|
$83.00
323.06% Upside
|
-12.2% |
|
IVVD
Invivyd
|
Dec 15, 2021 | HOLD |
Buy
+920.9% avg upside
8 analysts
|
— | -74.7% |
|
DE:MRK
Merck KGaA
|
Dec 07, 2021 | HOLD |
Buy
-2.3% avg upside
33 analysts
|
— | · |
|
CH:NOVN
Novartis AG
|
Feb 25, 2020 | HOLD |
Buy
-13.7% avg upside
31 analysts
|
— | · |
|
NVS
Novartis
|
Oct 08, 2018 | HOLD |
Buy
-11.7% avg upside
24 analysts
|
— | +15.3% |
|
ARDX
Ardelyx
|
Oct 17, 2017 | BUY |
Strong Buy
+163.7% avg upside
21 analysts
|
$13.00
152.92% Upside
|
-28.5% |
|
PFE
Pfizer
|
Sep 08, 2016 | HOLD |
Buy
+37.0% avg upside
45 analysts
|
$37.00
51.09% Upside
|
+2.2% |
|
NPKI
NPK International
|
Aug 24, 2016 | BUY |
Strong Buy
+75.9% avg upside
12 analysts
|
$108.00
653.66% Upside
|
-0.8% |
|
KYNB
Kyntra Bio
|
Aug 09, 2016 | BUY |
Strong Buy
+324.8% avg upside
15 analysts
|
$52.00
607.93% Upside
|
+127.5% |
|
ALNY
Alnylam Pharma
|
Jul 15, 2016 | BUY |
Strong Buy
+19.8% avg upside
51 analysts
|
— | +22.1% |
|
REGN
Regeneron
|
Jul 15, 2016 | BUY |
Strong Buy
+16.5% avg upside
58 analysts
|
— | +35.1% |
|
AMGN
Amgen
|
Jul 15, 2016 | HOLD |
Buy
-17.0% avg upside
57 analysts
|
— | +11.4% |
|
JNJ
Johnson & Johnson
|
Jun 14, 2016 | BUY |
Strong Buy
-13.2% avg upside
36 analysts
|
$125.00
51.57% Downside
|
+16.4% |
|
AGIO
Agios Pharma
|
Jun 13, 2016 | HOLD |
Buy
+50.0% avg upside
29 analysts
|
$56.00
38.09% Upside
|
-2.4% |
|
CLDX
Celldex
|
Mar 07, 2016 | HOLD |
Strong Buy
+1.6% avg upside
28 analysts
|
$4.00
89.57% Downside
|
-8.7% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.